期刊文献+

螺内酯致流涎增多

Salivation increased due to spironolactone
暂未订购
导出
摘要 1例84岁男性患者,因无明显诱因出现咳嗽、咳痰,偶伴喘憋,活动后明显,诊断为慢性支气管炎,使用抗菌药物后病情好转,此后因心率快导致活动耐力进行性下降。为改善心功能,在常规用药不变的情况下加用小剂量的螺内酯20 mgqd。用药3 d后患者流涎明显增多,反复误吸,治疗5 d后心功能有所改善,停用螺内酯,流涎明显减少,以后逐渐恢复正常。3个月后,患者无明显诱因出现体温升高,心率增快,一般活动后可出现乏力、心悸、呼吸困难,再次住院。予以注射用美罗培南治疗,为进一步改善心功能,口服地高辛0.125 g qd,同时加用螺内酯片20 mg qd,用药第3天患者流涎明显增多,考虑与使用螺内酯有关,即停药,2 d后流涎症状逐渐消失。 One 84-year-old man with cough, expectoration, wheeze especially after activity, was diagnosed as chronic bronchitis. The condition of the patient was improved after the use of antimicrobial drugs. The reduced exercise tolerance occurred due to reduced heart function associated with pulmonary infection. Then the spironolactone with a dose of 20 mg once a day was administered to improve cardiac function. Three days later, there was obviously increased salivation resulted in aspiration. The spironolactone was subsequently stopped and antibiotic therapy was continued. The patient's salivation gradually reduced and the general condition became better. After 3 months, the patient suffered the fever and cough with yellowish sputum, heart rate increased, feeble, palpitation, dyspnea again. Meropenem for injection was used, and the digoxin 0.125 g once a day, spironolactone 20 mg once a day were added to sustain the cardiac function. The salivation occurred again after 3 days use of spironolactone. The symptom of salivation disappeared after spironolactone withdrawal for 2 days.
作者 霍霞
出处 《中国药物应用与监测》 CAS 2013年第4期242-243,共2页 Chinese Journal of Drug Application and Monitoring
关键词 螺内酯 流涎增多 药品不良反应 Spironolactone Salivation increased Adverse drug reaction
  • 相关文献

参考文献5

二级参考文献14

  • 1黄志明.头孢哌酮钠致急性腹痛1例[J].中国药物应用与监测,2006,3(6):4-4. 被引量:2
  • 2刘宜柔,张宜东.螺内酯致男性乳房发育症7例分析[J].中国实用乡村医生杂志,2006,13(10):41-41. 被引量:3
  • 3齐金秋,岳一涛.头孢尼西钠致肌肉关节疼痛1例[J].中国药物应用与监测,2007,4(4):11-11. 被引量:5
  • 4McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure:randomized evaluation of strategies for left ventricular dysfunction(RESOLVD) pilot study. The RESOLVD Pilot Study Investigators[ J ]. Circulation, 1999,100 (10) : 1056 - 1064.
  • 5McMahon EG. Recent studies with eplerenone. A novel selective aldosterone receptor antagonist [ J ]. Curr Opin Pharmacol, 2001,1 (2):190 -196.
  • 6Zannad F. Angiotensin-converting enzyme inhabit and spironolactone combination therapy: new objectives in congestive heart failure treatment[ J]. Am J Cardiol, 1993,71 (suppl) :34A - 39A.
  • 7Zannad F, Dousset B, Alla F. Treatment of congestive heart failure :interfering the aldosterone cardiac extracellular matrix relationship[ J ]. Hypertension, 2001,38 (5) : 1227 - 1232.
  • 8Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with sever heart failure : Randomized Aldactone Evaluation Study Investigators [ J]. N Engl J Med,1999,341 (10) :709 - 717.
  • 9Pitt B, Remme W, Zannad F,et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction[ J ]. N Eng J Med,2003,348 (14) : 1309 -1321.
  • 10Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass[J]. Lancet, 2001,357(9265) :1354 - 1356.

共引文献436

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部